25 XP   0   0   10

Samjin Pharm
Buy, Hold or Sell?

Let's analyse Samjin Pharm together

PenkeI guess you are interested in Samjin Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Samjin Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Samjin Pharm

I send you an email if I find something interesting about Samjin Pharm.

Quick analysis of Samjin Pharm (30 sec.)










What can you expect buying and holding a share of Samjin Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
33.3%

What is your share worth?

Current worth
₩20,772.21
Expected worth in 1 year
₩21,992.05
How sure are you?
70.4%

+ What do you gain per year?

Total Gains per Share
₩1,219.85
Return On Investment
6.1%

For what price can you sell your share?

Current Price per Share
₩19,880.00
Expected price per share
₩0 - ₩20,900
How sure are you?
50%

1. Valuation of Samjin Pharm (5 min.)




Live pricePrice per Share (EOD)

₩19,880.00

Intrinsic Value Per Share

₩-19,285.59 - ₩-22,284.23

Total Value Per Share

₩1,486.62 - ₩-1,512.02

2. Growth of Samjin Pharm (5 min.)




Is Samjin Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$185.7m$168.5m$18.7m10.0%

How much money is Samjin Pharm making?

Current yearPrevious yearGrowGrow %
Making money$3.5m$2.8m$693.8k19.7%
Net Profit Margin6.9%6.1%--

How much money comes from the company's main activities?

3. Financial Health of Samjin Pharm (5 min.)




What can you expect buying and holding a share of Samjin Pharm? (5 min.)

Welcome investor! Samjin Pharm's management wants to use your money to grow the business. In return you get a share of Samjin Pharm.

What can you expect buying and holding a share of Samjin Pharm?

First you should know what it really means to hold a share of Samjin Pharm. And how you can make/lose money.

Speculation

The Price per Share of Samjin Pharm is ₩19,880. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Samjin Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Samjin Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩20,772.21. Based on the TTM, the Book Value Change Per Share is ₩304.96 per quarter. Based on the YOY, the Book Value Change Per Share is ₩407.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Samjin Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.400.0%0.270.0%0.220.0%0.290.0%0.350.0%
Usd Book Value Change Per Share-0.050.0%0.210.0%0.290.0%0.140.0%0.540.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.080.0%
Usd Total Gains Per Share-0.050.0%0.210.0%0.290.0%0.140.0%0.610.0%
Usd Price Per Share15.12-15.23-17.79-18.07-20.88-
Price to Earnings Ratio9.35-31.93-20.56-14.59-14.49-
Price-to-Total Gains Ratio-295.37-2,880.31-14.17-534.90-389.06-
Price to Book Ratio1.04-1.05-1.37-1.49-1.83-
Price-to-Total Gains Ratio-295.37-2,880.31-14.17-534.90-389.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.916
Number of shares71
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.210.14
Usd Total Gains Per Share0.210.14
Gains per Quarter (71 shares)15.169.80
Gains per Year (71 shares)60.6339.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10615103929
2012111207868
301821730118107
402432340157146
503032950196185
603643560235224
704244170274263
804854780313302
905465390353341
1006066000392380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.01.00.090.9%17.02.00.089.5%25.02.00.092.6%25.02.00.092.6%
Book Value Change Per Share3.01.00.075.0%7.04.00.063.6%11.08.00.057.9%19.08.00.070.4%19.08.00.070.4%
Dividend per Share1.00.03.025.0%1.00.010.09.1%2.00.017.010.5%9.00.018.033.3%9.00.018.033.3%
Total Gains per Share3.01.00.075.0%7.04.00.063.6%11.08.00.057.9%19.08.00.070.4%19.08.00.070.4%

Fundamentals of Samjin Pharm

About Samjin Pharm

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 21:39:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Samjin Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Samjin Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.6% means that ₩0.10 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Samjin Pharm:

  • The MRQ is 9.6%. The company is making a profit. +1
  • The TTM is 6.9%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.6%TTM6.9%+2.7%
TTM6.9%YOY6.1%+0.8%
TTM6.9%5Y8.0%-1.1%
5Y8.0%10Y10.0%-2.0%
1.1.2. Return on Assets

Shows how efficient Samjin Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.8% Return on Assets means that Samjin Pharm generated ₩0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Samjin Pharm:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.2%+0.6%
TTM1.2%YOY1.1%+0.1%
TTM1.2%5Y1.7%-0.5%
5Y1.7%10Y2.3%-0.6%
1.1.3. Return on Equity

Shows how efficient Samjin Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.8% Return on Equity means Samjin Pharm generated ₩0.03 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Samjin Pharm:

  • The MRQ is 2.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.8%TTM1.9%+0.9%
TTM1.9%YOY1.7%+0.2%
TTM1.9%5Y2.3%-0.5%
5Y2.3%10Y3.1%-0.8%

1.2. Operating Efficiency of Samjin Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Samjin Pharm is operating .

  • Measures how much profit Samjin Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Samjin Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y7.9%-7.9%
5Y7.9%10Y11.4%-3.5%
1.2.2. Operating Ratio

Measures how efficient Samjin Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are ₩1.49 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Samjin Pharm:

  • The MRQ is 1.492. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.531. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.492TTM1.531-0.039
TTM1.531YOY1.487+0.043
TTM1.5315Y1.427+0.104
5Y1.42710Y1.375+0.052

1.3. Liquidity of Samjin Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Samjin Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.01 means the company has ₩1.01 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Samjin Pharm:

  • The MRQ is 1.011. The company is just able to pay all its short-term debts.
  • The TTM is 1.163. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.011TTM1.163-0.152
TTM1.163YOY1.894-0.731
TTM1.1635Y3.067-1.904
5Y3.06710Y3.221-0.154
1.3.2. Quick Ratio

Measures if Samjin Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.43 means the company can pay off ₩0.43 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Samjin Pharm:

  • The MRQ is 0.427. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.474. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.427TTM0.474-0.048
TTM0.474YOY0.752-0.277
TTM0.4745Y1.216-0.741
5Y1.21610Y1.424-0.208

1.4. Solvency of Samjin Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Samjin Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Samjin Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.37 means that Samjin Pharm assets are financed with 36.8% credit (debt) and the remaining percentage (100% - 36.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Samjin Pharm:

  • The MRQ is 0.368. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.365. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.368TTM0.365+0.003
TTM0.365YOY0.345+0.020
TTM0.3655Y0.273+0.092
5Y0.27310Y0.257+0.016
1.4.2. Debt to Equity Ratio

Measures if Samjin Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 58.2% means that company has ₩0.58 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Samjin Pharm:

  • The MRQ is 0.582. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.576. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.582TTM0.576+0.007
TTM0.576YOY0.528+0.048
TTM0.5765Y0.390+0.186
5Y0.39010Y0.358+0.032

2. Market Valuation of Samjin Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Samjin Pharm generates.

  • Above 15 is considered overpriced but always compare Samjin Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 9.35 means the investor is paying ₩9.35 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Samjin Pharm:

  • The EOD is 8.608. Based on the earnings, the company is underpriced. +1
  • The MRQ is 9.353. Based on the earnings, the company is underpriced. +1
  • The TTM is 31.930. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.608MRQ9.353-0.745
MRQ9.353TTM31.930-22.577
TTM31.930YOY20.557+11.373
TTM31.9305Y14.586+17.344
5Y14.58610Y14.493+0.093
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Samjin Pharm:

  • The EOD is -10.073. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.945. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -112.740. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.073MRQ-10.945+0.872
MRQ-10.945TTM-112.740+101.796
TTM-112.740YOY-33.695-79.045
TTM-112.7405Y-28.447-84.293
5Y-28.44710Y-15.415-13.032
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Samjin Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.04 means the investor is paying ₩1.04 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Samjin Pharm:

  • The EOD is 0.957. Based on the equity, the company is cheap. +2
  • The MRQ is 1.040. Based on the equity, the company is underpriced. +1
  • The TTM is 1.051. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.957MRQ1.040-0.083
MRQ1.040TTM1.051-0.011
TTM1.051YOY1.373-0.322
TTM1.0515Y1.485-0.435
5Y1.48510Y1.826-0.341
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Samjin Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---73.138304.960-124%407.397-118%197.114-137%769.341-110%
Book Value Per Share--20772.21120711.103+0%18522.536+12%17702.160+17%16848.393+23%
Current Ratio--1.0111.163-13%1.894-47%3.067-67%3.221-69%
Debt To Asset Ratio--0.3680.365+1%0.345+7%0.273+35%0.257+43%
Debt To Equity Ratio--0.5820.576+1%0.528+10%0.390+49%0.358+63%
Dividend Per Share--0.0090.002+300%-+100%0.000+1787%107.612-100%
Eps--577.370387.547+49%310.289+86%411.466+40%505.514+14%
Free Cash Flow Per Share---493.389-240.245-51%-345.290-30%-293.695-40%-12.300-98%
Free Cash Flow To Equity Per Share---493.389-240.245-51%-345.290-30%-293.695-40%-108.572-78%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---22284.231--------
Intrinsic Value_10Y_min---19285.592--------
Intrinsic Value_1Y_max---2179.973--------
Intrinsic Value_1Y_min---2141.231--------
Intrinsic Value_3Y_max---6590.378--------
Intrinsic Value_3Y_min---6290.903--------
Intrinsic Value_5Y_max---11049.587--------
Intrinsic Value_5Y_min---10252.459--------
Market Cap253967000000.000-9%275940000000.000281067249200.000-2%330299229300.000-16%331222654457.895-17%382147932766.667-28%
Net Profit Margin--0.0960.069+39%0.061+57%0.080+19%0.100-5%
Operating Margin----0%-0%0.079-100%0.114-100%
Operating Ratio--1.4921.531-3%1.487+0%1.427+5%1.375+9%
Pb Ratio0.957-9%1.0401.051-1%1.373-24%1.485-30%1.826-43%
Pe Ratio8.608-9%9.35331.930-71%20.557-55%14.586-36%14.493-35%
Price Per Share19880.000-9%21600.00021762.500-1%25416.667-15%25807.895-16%29829.630-28%
Price To Free Cash Flow Ratio-10.073+8%-10.945-112.740+930%-33.695+208%-28.447+160%-15.415+41%
Price To Total Gains Ratio-271.849+8%-295.3692880.305-110%14.166-2185%534.898-155%389.060-176%
Quick Ratio--0.4270.474-10%0.752-43%1.216-65%1.424-70%
Return On Assets--0.0180.012+47%0.011+60%0.017+3%0.023-25%
Return On Equity--0.0280.019+49%0.017+66%0.023+19%0.031-10%
Total Gains Per Share---73.129304.963-124%407.397-118%197.115-137%876.954-108%
Usd Book Value--185755498.355187263145.552-1%168552726.837+10%159194268.541+17%151294946.820+23%
Usd Book Value Change Per Share---0.0510.213-124%0.285-118%0.138-137%0.539-110%
Usd Book Value Per Share--14.54114.498+0%12.966+12%12.392+17%11.794+23%
Usd Dividend Per Share--0.0000.000+300%-+100%0.000+1787%0.075-100%
Usd Eps--0.4040.271+49%0.217+86%0.288+40%0.354+14%
Usd Free Cash Flow---4412134.440-2167842.362-51%-3183818.195-28%-2645627.211-40%-123551.690-97%
Usd Free Cash Flow Per Share---0.345-0.168-51%-0.242-30%-0.206-40%-0.009-98%
Usd Free Cash Flow To Equity Per Share---0.345-0.168-51%-0.242-30%-0.206-40%-0.076-78%
Usd Market Cap177776900.000-9%193158000.000196747074.440-2%231209460.510-16%231855858.121-17%267503552.937-28%
Usd Price Per Share13.916-9%15.12015.234-1%17.792-15%18.066-16%20.881-28%
Usd Profit--5163134.0533516231.856+47%2822333.514+83%3697698.970+40%4533343.886+14%
Usd Revenue--54037447.91951122493.403+6%46427285.744+16%44883411.913+20%44573350.848+21%
Usd Total Gains Per Share---0.0510.213-124%0.285-118%0.138-137%0.614-108%
 EOD+4 -4MRQTTM+15 -19YOY+15 -195Y+15 -2010Y+10 -25

3.2. Fundamental Score

Let's check the fundamental score of Samjin Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-158.608
Price to Book Ratio (EOD)Between0-10.957
Net Profit Margin (MRQ)Greater than00.096
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.427
Current Ratio (MRQ)Greater than11.011
Debt to Asset Ratio (MRQ)Less than10.368
Debt to Equity Ratio (MRQ)Less than10.582
Return on Equity (MRQ)Greater than0.150.028
Return on Assets (MRQ)Greater than0.050.018
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Samjin Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.483
Ma 20Greater thanMa 5020,002.000
Ma 50Greater thanMa 10020,270.800
Ma 100Greater thanMa 20020,734.400
OpenGreater thanClose19,770.000
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302023-03-312023-06-302023-09-302023-12-31
Other Current Liabilities  000010000



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets419,901,237
Total Liabilities154,536,239
Total Stockholder Equity265,364,997
 As reported
Total Liabilities 154,536,239
Total Stockholder Equity+ 265,364,997
Total Assets = 419,901,237

Assets

Total Assets419,901,237
Total Current Assets146,180,495
Long-term Assets273,720,742
Total Current Assets
Cash And Cash Equivalents 2,401,474
Short-term Investments 1,605,000
Net Receivables 60,089,381
Inventory 79,602,803
Total Current Assets  (as reported)146,180,495
Total Current Assets  (calculated)143,698,658
+/- 2,481,837
Long-term Assets
Property Plant Equipment 191,639,731
Intangible Assets 20,300,419
Long-term Assets Other 0
Long-term Assets  (as reported)273,720,742
Long-term Assets  (calculated)211,940,151
+/- 61,780,591

Liabilities & Shareholders' Equity

Total Current Liabilities144,550,214
Long-term Liabilities9,986,025
Total Stockholder Equity265,364,997
Total Current Liabilities
Short Long Term Debt 113,833,280
Accounts payable 11,136,855
Other Current Liabilities 0
Total Current Liabilities  (as reported)144,550,214
Total Current Liabilities  (calculated)124,970,135
+/- 19,580,079
Long-term Liabilities
Long term Debt 4,166,640
Capital Lease Obligations Min Short Term Debt638,413
Long-term Liabilities Other 1,405,424
Long-term Liabilities  (as reported)9,986,025
Long-term Liabilities  (calculated)6,210,477
+/- 3,775,548
Total Stockholder Equity
Retained Earnings 240,859,937
Total Stockholder Equity (as reported)265,364,997
Total Stockholder Equity (calculated)240,859,937
+/- 24,505,060
Other
Capital Stock13,900,000
Common Stock Shares Outstanding 12,775
Net Debt 115,598,446
Net Invested Capital 383,364,917
Net Working Capital 1,630,281
Property Plant and Equipment Gross 293,892,452



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
227,572,907
233,701,956
228,040,561
237,189,542
241,847,412
253,290,999
251,113,512
264,836,407
262,901,437
239,483,506
239,471,904
244,151,048
256,853,473
261,880,228
269,575,154
269,033,498
284,541,295
292,361,904
325,342,583
332,495,965
355,330,657
354,712,549
392,592,166
421,462,663
421,773,570
422,725,662
419,901,237
419,901,237422,725,662421,773,570421,462,663392,592,166354,712,549355,330,657332,495,965325,342,583292,361,904284,541,295269,033,498269,575,154261,880,228256,853,473244,151,048239,471,904239,483,506262,901,437264,836,407251,113,512253,290,999241,847,412237,189,542228,040,561233,701,956227,572,907
   > Total Current Assets 
145,839,149
150,779,292
143,178,150
152,760,540
157,270,717
169,422,333
166,540,716
179,645,759
173,534,835
148,029,768
146,106,769
150,110,382
159,780,549
161,403,671
162,253,016
146,859,959
150,702,034
143,987,216
156,263,151
139,871,864
145,339,994
138,276,116
134,359,820
151,651,312
152,557,837
156,622,117
146,180,495
146,180,495156,622,117152,557,837151,651,312134,359,820138,276,116145,339,994139,871,864156,263,151143,987,216150,702,034146,859,959162,253,016161,403,671159,780,549150,110,382146,106,769148,029,768173,534,835179,645,759166,540,716169,422,333157,270,717152,760,540143,178,150150,779,292145,839,149
       Cash And Cash Equivalents 
11,910,001
18,841,938
5,657,512
13,304,827
21,914,820
36,136,118
30,447,957
40,593,247
20,846,307
17,743,847
21,546,226
31,895,624
40,462,024
38,699,822
31,760,208
18,909,481
24,005,126
14,521,805
17,831,981
7,940,719
19,439,611
14,380,902
3,594,129
2,352,588
2,823,109
2,398,092
2,401,474
2,401,4742,398,0922,823,1092,352,5883,594,12914,380,90219,439,6117,940,71917,831,98114,521,80524,005,12618,909,48131,760,20838,699,82240,462,02431,895,62421,546,22617,743,84720,846,30740,593,24730,447,95736,136,11821,914,82013,304,8275,657,51218,841,93811,910,001
       Short-term Investments 
7,120,000
6,565,000
11,017,677
6,750,733
6,500,000
4,460,000
4,425,000
3,660,000
4,430,000
4,090,000
5,170,000
5,390,000
6,005,000
5,930,000
7,065,000
5,580,000
4,710,000
4,390,000
2,580,000
3,770,000
3,230,000
3,130,000
4,210,000
6,983,711
4,058,078
1,572,842
1,605,000
1,605,0001,572,8424,058,0786,983,7114,210,0003,130,0003,230,0003,770,0002,580,0004,390,0004,710,0005,580,0007,065,0005,930,0006,005,0005,390,0005,170,0004,090,0004,430,0003,660,0004,425,0004,460,0006,500,0006,750,73311,017,6776,565,0007,120,000
       Net Receivables 
83,784,224
79,489,958
79,384,938
84,188,370
76,498,550
75,277,842
74,084,985
72,952,799
61,558,790
59,720,879
54,996,607
53,089,205
51,684,578
51,793,446
51,161,943
51,295,567
49,997,205
54,264,219
71,705,608
56,670,961
50,975,131
50,990,664
53,563,441
57,372,103
57,282,564
57,619,784
60,089,381
60,089,38157,619,78457,282,56457,372,10353,563,44150,990,66450,975,13156,670,96171,705,60854,264,21949,997,20551,295,56751,161,94351,793,44651,684,57853,089,20554,996,60759,720,87961,558,79072,952,79974,084,98575,277,84276,498,55084,188,37079,384,93879,489,95883,784,224
       Inventory 
42,312,376
44,997,852
46,362,082
47,672,263
51,436,534
52,590,545
56,732,225
61,073,579
61,613,980
63,477,811
61,361,221
58,032,135
59,824,792
62,888,028
70,631,124
70,065,175
70,164,712
69,388,761
62,653,432
69,709,188
70,328,266
68,455,631
71,414,856
72,908,758
76,146,771
83,692,183
79,602,803
79,602,80383,692,18376,146,77172,908,75871,414,85668,455,63170,328,26669,709,18862,653,43269,388,76170,164,71270,065,17570,631,12462,888,02859,824,79258,032,13561,361,22163,477,81161,613,98061,073,57956,732,22552,590,54551,436,53447,672,26346,362,08244,997,85242,312,376
       Other Current Assets 
674,277
836,459
721,993
844,347
884,993
905,935
814,446
1,342,363
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000011,342,363814,446905,935884,993844,347721,993836,459674,277
   > Long-term Assets 
0
0
0
0
0
0
0
0
89,366,602
91,453,738
93,365,135
94,040,666
97,072,924
100,476,557
107,322,138
122,173,538
133,839,261
148,374,688
169,079,432
192,624,101
209,990,663
216,436,434
258,232,346
269,811,351
269,215,733
266,103,545
273,720,742
273,720,742266,103,545269,215,733269,811,351258,232,346216,436,434209,990,663192,624,101169,079,432148,374,688133,839,261122,173,538107,322,138100,476,55797,072,92494,040,66693,365,13591,453,73889,366,60200000000
       Property Plant Equipment 
72,398,449
73,522,123
75,877,675
75,787,881
74,867,570
74,067,341
73,432,030
73,773,997
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196,253,158
197,233,554
195,650,162
192,134,924
191,639,731
191,639,731192,134,924195,650,162197,233,554196,253,1580000000000000073,773,99773,432,03074,067,34174,867,57075,787,88175,877,67573,522,12372,398,449
       Long Term Investments 
4,615,448
4,690,448
4,194,948
4,020,075
4,671,249
4,426,115
5,805,772
5,948,255
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000005,948,2555,805,7724,426,1154,671,2494,020,0754,194,9484,690,4484,615,448
       Intangible Assets 
3,922,595
3,912,826
3,992,522
3,806,747
3,970,456
4,121,573
4,135,091
4,123,139
5,766,781
6,842,177
6,849,909
7,518,360
7,471,321
8,082,408
8,332,597
8,496,253
9,549,028
9,671,278
10,100,007
10,312,564
10,305,690
10,313,624
10,318,131
10,299,685
10,361,885
10,318,427
20,300,419
20,300,41910,318,42710,361,88510,299,68510,318,13110,313,62410,305,69010,312,56410,100,0079,671,2789,549,0288,496,2538,332,5978,082,4087,471,3217,518,3606,849,9096,842,1775,766,7814,123,1394,135,0914,121,5733,970,4563,806,7473,992,5223,912,8263,922,595
       Long-term Assets Other 
0
0
0
0
0
0
0
0
89,366,602
1
1
0
0
0
0
-1
0
0
0
0
0
0
0
0
0
0
0
00000000000-100001189,366,60200000000
> Total Liabilities 
57,877,988
63,907,428
48,807,965
51,649,065
48,380,155
59,693,371
45,286,421
47,315,957
55,740,416
43,255,126
33,830,369
46,676,832
60,556,576
57,372,949
59,434,273
55,577,253
74,127,327
73,744,909
90,904,675
98,327,947
127,376,881
122,571,672
130,317,990
149,451,460
155,373,988
156,426,326
154,536,239
154,536,239156,426,326155,373,988149,451,460130,317,990122,571,672127,376,88198,327,94790,904,67573,744,90974,127,32755,577,25359,434,27357,372,94960,556,57646,676,83233,830,36943,255,12655,740,41647,315,95745,286,42159,693,37148,380,15551,649,06548,807,96563,907,42857,877,988
   > Total Current Liabilities 
46,663,894
52,043,676
39,361,382
41,351,972
43,206,199
52,893,690
39,627,216
41,856,951
47,502,871
37,919,653
28,320,422
30,707,237
44,245,146
37,443,720
39,110,776
33,935,282
41,448,045
38,152,249
42,269,849
49,514,224
74,192,427
70,149,526
76,647,081
102,580,526
141,279,005
144,523,435
144,550,214
144,550,214144,523,435141,279,005102,580,52676,647,08170,149,52674,192,42749,514,22442,269,84938,152,24941,448,04533,935,28239,110,77637,443,72044,245,14630,707,23728,320,42237,919,65347,502,87141,856,95139,627,21652,893,69043,206,19941,351,97239,361,38252,043,67646,663,894
       Short-term Debt 
9,000,000
9,000,000
4,000,000
4,000,000
4,000,000
3,000,000
0
0
155,687
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000155,687003,000,0004,000,0004,000,0004,000,0009,000,0009,000,000
       Short Long Term Debt 
9,000,000
9,000,000
4,000,000
4,000,000
4,000,000
3,000,000
0
0
0
0
0
0
0
0
0
0
0
5,000,000
5,000,000
14,166,800
31,250,120
38,333,440
38,333,280
53,333,280
103,333,280
105,333,280
113,833,280
113,833,280105,333,280103,333,28053,333,28038,333,28038,333,44031,250,12014,166,8005,000,0005,000,000000000000003,000,0004,000,0004,000,0004,000,0009,000,0009,000,000
       Accounts payable 
20,506,951
19,010,267
19,956,287
23,394,044
21,422,391
22,986,509
22,524,023
26,816,127
20,407,030
20,957,969
12,565,346
15,667,088
17,563,838
19,180,911
18,119,421
12,710,103
11,295,630
11,857,511
10,632,849
12,236,230
11,319,774
12,247,871
15,409,677
16,604,152
16,148,353
18,552,972
11,136,855
11,136,85518,552,97216,148,35316,604,15215,409,67712,247,87111,319,77412,236,23010,632,84911,857,51111,295,63012,710,10318,119,42119,180,91117,563,83815,667,08812,565,34620,957,96920,407,03026,816,12722,524,02322,986,50921,422,39123,394,04419,956,28719,010,26720,506,951
       Other Current Liabilities 
16,544,290
23,417,211
14,407,859
13,311,733
17,015,522
25,878,885
15,928,103
14,368,420
-1
0
0
0
-1
1
0
0
0
0
0
1
0
1
0
0
1
0
0
00100101000001-1000-114,368,42015,928,10325,878,88517,015,52213,311,73314,407,85923,417,21116,544,290
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
8,237,544
5,335,474
5,509,947
15,969,596
16,311,430
19,929,229
20,323,497
21,641,971
32,679,282
35,592,660
48,634,826
48,813,723
53,184,454
52,422,147
53,670,909
46,870,934
14,094,984
11,902,891
9,986,025
9,986,02511,902,89114,094,98446,870,93453,670,90952,422,14753,184,45448,813,72348,634,82635,592,66032,679,28221,641,97120,323,49719,929,22916,311,43015,969,5965,509,9475,335,4748,237,54400000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
281,248
291,313
1,687,331
1,488,985
1,503,777
1,445,219
1,733,040
1,535,476
1,365,357
1,124,007
852,749
505,376
939,149
900,744
792,013
739,613
663,320
674,350
638,413
638,413674,350663,320739,613792,013900,744939,149505,376852,7491,124,0071,365,3571,535,4761,733,0401,445,2191,503,7771,488,9851,687,331291,313281,24800000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,405,424
1,405,42400000000000000000000000000
> Total Stockholder Equity
169,694,919
169,794,528
179,232,596
185,540,478
193,467,257
193,597,628
205,827,090
217,520,451
207,161,020
196,228,379
205,641,535
197,474,215
196,296,896
204,507,278
210,140,882
213,456,244
210,413,968
218,616,995
234,437,908
234,168,018
227,953,776
232,140,877
262,274,176
272,011,202
266,399,582
266,299,335
265,364,997
265,364,997266,299,335266,399,582272,011,202262,274,176232,140,877227,953,776234,168,018234,437,908218,616,995210,413,968213,456,244210,140,882204,507,278196,296,896197,474,215205,641,535196,228,379207,161,020217,520,451205,827,090193,597,628193,467,257185,540,478179,232,596169,794,528169,694,919
   Common Stock
13,900,000
13,900,000
13,900,000
13,900,000
13,900,000
13,900,000
13,900,000
13,900,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000013,900,00013,900,00013,900,00013,900,00013,900,00013,900,00013,900,00013,900,000
   Retained Earnings 
138,162,742
138,039,440
147,759,982
158,279,536
165,964,048
165,873,642
180,969,104
192,441,688
174,677,940
163,527,661
172,723,179
164,334,375
162,978,694
171,010,714
176,465,955
180,087,982
195,651,423
203,854,450
219,675,364
219,405,473
213,191,231
217,378,332
221,658,931
236,948,625
237,356,254
240,498,719
240,859,937
240,859,937240,498,719237,356,254236,948,625221,658,931217,378,332213,191,231219,405,473219,675,364203,854,450195,651,423180,087,982176,465,955171,010,714162,978,694164,334,375172,723,179163,527,661174,677,940192,441,688180,969,104165,873,642165,964,048158,279,536147,759,982138,039,440138,162,742
   Capital Surplus 000000000000000000000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
15,370,903
15,593,815
15,816,725
16,039,636
16,218,430
16,439,207
13,573,207
13,793,984
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000013,793,98413,573,20716,439,20716,218,43016,039,63615,816,72515,593,81515,370,903



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue292,128,534
Cost of Revenue-175,447,298
Gross Profit116,681,236116,681,236
 
Operating Income (+$)
Gross Profit116,681,236
Operating Expense-271,644,178
Operating Income20,484,356-154,962,942
 
Operating Expense (+$)
Research Development4,167,289
Selling General Administrative41,462,921
Selling And Marketing Expenses0
Operating Expense271,644,17845,630,210
 
Net Interest Income (+$)
Interest Income89,360
Interest Expense-4,425,475
Other Finance Cost-1
Net Interest Income-4,336,114
 
Pretax Income (+$)
Operating Income20,484,356
Net Interest Income-4,336,114
Other Non-Operating Income Expenses0
Income Before Tax (EBT)15,557,13520,484,356
EBIT - interestExpense = -4,425,475
18,905,784
23,331,259
Interest Expense4,425,475
Earnings Before Interest and Taxes (EBIT)019,982,610
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax15,557,135
Tax Provision--3,348,649
Net Income From Continuing Ops18,905,78418,905,784
Net Income18,905,784
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net04,336,114
 

Technical Analysis of Samjin Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Samjin Pharm. The general trend of Samjin Pharm is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Samjin Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Samjin Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 19,990 < 19,990 < 20,900.

The bearish price targets are: .

Tweet this
Samjin Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Samjin Pharm. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Samjin Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Samjin Pharm. The current macd is -171.29043394.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Samjin Pharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Samjin Pharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Samjin Pharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Samjin Pharm Daily Moving Average Convergence/Divergence (MACD) ChartSamjin Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Samjin Pharm. The current adx is 16.49.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Samjin Pharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Samjin Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Samjin Pharm. The current sar is 19,370.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Samjin Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Samjin Pharm. The current rsi is 45.48. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Samjin Pharm Daily Relative Strength Index (RSI) ChartSamjin Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Samjin Pharm. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Samjin Pharm price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Samjin Pharm Daily Stochastic Oscillator ChartSamjin Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Samjin Pharm. The current cci is -43.20625611.

Samjin Pharm Daily Commodity Channel Index (CCI) ChartSamjin Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Samjin Pharm. The current cmo is -3.17197863.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Samjin Pharm Daily Chande Momentum Oscillator (CMO) ChartSamjin Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Samjin Pharm. The current willr is -50.48543689.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Samjin Pharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Samjin Pharm Daily Williams %R ChartSamjin Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Samjin Pharm.

Samjin Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Samjin Pharm. The current atr is 262.37.

Samjin Pharm Daily Average True Range (ATR) ChartSamjin Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Samjin Pharm. The current obv is 6,096,968.

Samjin Pharm Daily On-Balance Volume (OBV) ChartSamjin Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Samjin Pharm. The current mfi is 20.98.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Samjin Pharm Daily Money Flow Index (MFI) ChartSamjin Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Samjin Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Samjin Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Samjin Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.483
Ma 20Greater thanMa 5020,002.000
Ma 50Greater thanMa 10020,270.800
Ma 100Greater thanMa 20020,734.400
OpenGreater thanClose19,770.000
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Samjin Pharm with someone you think should read this too:
  • Are you bullish or bearish on Samjin Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Samjin Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Samjin Pharm

I send you an email if I find something interesting about Samjin Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Samjin Pharm.

Receive notifications about Samjin Pharm in your mailbox!